Skip to main content
Premium Trial:

Request an Annual Quote

NY State Clears Cancer Genetics NGS Lymphoma Panel

NEW YORK (GenomeWeb) – Cancer Genetics (CGI) announced today that it has received New York State approval for Focus::CLL, a next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic lymphoma designed to offer information related to patient stratification, disease management, and treatment selection.

Focus::CLL targets actionable markers in seven genes — TP53, NOTCH1, SF3B1, BIRC3, ATM, MYD88, and CARD11 — and was launched in late 2014. While the panel is performed at a CLIA-certified laboratory, additional licenses are required to offer such tests in New York.

"This approval is a testament to CGI's ability to provide NGS panels that meet the highest quality standards," President and CEO Panna Sharma said in a statement. "Focus::CLL is currently being used in multiple global clinical trials by leading biotech and pharmaceutical companies to aid in patient monitoring and disease understanding."